Liver Disease

There was statistically significant and clinically meaningful overall survival benefit vs sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) in top-line results from a phase 3 trial.

Individuals who drink more than 3 cups of coffee a day had decreased liver stiffness.

The pathway outlines a 4-step screening process for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Comparing liver cancer survival across high-income countries has been difficult due to different standard and coding practices

Maralixibat is the first treatment approved for cholestatic pruritus in patients with Alagille syndrome who are 1 year or older.

Findings from this new study are the result of an investigation into over 360 children, many with active hepatitis, elevated alanine aminotransferase levels, and an immune active phenotype.

Researchers argue that Onodera’s prognostic nutritional index, calculated by lymphocytes and serum albumin to determine nutritional and immune status, is a straightforward method for use among patients undergoing liver surgery.

Patients who are treated with direct-acting antivirals to treat hepatitis C virus (HCV) are still at risk of developing hepatocellular carcinoma (HCC).

Although some cancers are falling for rural US residents, liver cancer is on the rise, a new study has found.

Patients with chronic liver diseases have been at a high risk of more severe COVID-19 outcomes, but the pandemic has meant the management of these diseases has received less attention.

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

This new study from investigators at Tel Aviv University looked at predictors of nonalcoholic fatty liver disease (NAFLD) among children and adolescents considered obese, because its predictors are not well known in this group.

Hepatocellular carcinoma (HCC) is challenging to diagnose and has an evolving treatment landscape, which makes a multidisciplinary approach to care important to ensure high-quality care and the best patient outcomes.

Research shows how socioeconomic status can affect prognosis among patients with hepatocellular carcinoma (HCC).

Results of a score-matched analysis showed individuals with hepatocellular cancer reported poor mental health as time progressed after diagnosis.

Researchers said the blood test offers an earlier warning of hepatocellular carcinoma than current methods.

Sifting through large quantities of data using artificial intelligence (AI) could one day change how nonalcoholic fatty liver disease (NAFLD) is diagnosed, managed, and treated, according to a recent review.

Early responders to the World Trade Center after the 9/11 attacks are associated with a higher likelihood of liver disease, according to a long-term follow-up of responders.

Using a systems biology approach, the researchers discovered 64 genes shared between non-alcoholic fatty liver disease (NAFLD) and hypertension, considered to be core genes for the 2 conditions.

Multidisciplinary care is an ideal way to management non-alcoholic fatty liver disease (NAFLD) because it is a complex disease associated with numerous comorbidities and necessitating lifestyle changes.

Patients with concurrent fatty liver disease and chronic hepatitis B exhibited higher cumulative rates of hepatitis B surface antigen seroclearance and lower cumulative rates of cirrhosis and hepatocellular carcinoma (HCC) across a 10-year period.

Patient-reported outcome measures may have a small impact on predicting which patients with cirrhosis will be readmitted to the hospital.

One diagnosis challenge is that there is no specific biomarker, either for autoimmune hepatitis (AIH) or metabolic-associated fatty liver disease (MAFLD), either alone or if they exist concurrently.

A new report is issuing a call to action to develop a global strategy to address the growing issue of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.